Spectrum Pharmaceuticals, Inc. Announces the USPTO Has Granted Five-Year Extension for FOLOTYN® Patent

Published: Oct 08, 2012

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN® (pralatrexate injection). The extension was granted through the Hatch-Waxman Act and postpones the original July 16, 2017 expiration date to July 16, 2022.

Back to news